Research
Research on IMPDH2-related disorders is limited but we are fortunate that some of the effects of alterations in the IMPDH2 gene have been studied. Below you’ll find a link to published research papers alongside a short summary generated by ChatGPT.
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somite organization
Published: December 2025
Summary (AI Generated):
This study looked at changes (mutations) in a gene called IMPDH2 and how those changes can affect the brain and development. The IMPDH2 gene gives instructions for making a protein that helps cells make important building blocks needed for growth and normal cell function.
Researchers studied people who had rare changes in the IMPDH2 gene and had problems such as movement disorders, dystonia (muscle twisting and uncontrolled movements), and other problems with brain development. They wanted to understand why these genetic changes cause disease.
The researchers found that many disease-causing IMPDH2 mutations change how the IMPDH2 protein works. Normally, the body has ways to control this protein so it does not become too active. The study showed that these mutations can make IMPDH2 lose this control and become too active. This may upset the balance of important molecules needed by brain cells.
The study also found that different IMPDH2 mutations can affect the protein in different ways. Some mutations change the shape of the protein, while others affect how well the protein can be controlled. These changes may explain why people with IMPDH2-related disease can have different symptoms and different levels of disability.
This research helps scientists better understand why IMPDH2 mutations cause neurological disease. It may also help researchers look for future treatments that could restore balance to the IMPDH2 pathway. However, more research is needed before any specific treatments are available.
In simple terms: This study shows that IMPDH2-related disease happens because changes in the IMPDH2 gene can cause an important cell protein to work incorrectly. When this happens, brain development and movement can be affected. Understanding exactly how the protein changes is an important step toward finding better care and possible treatments in the future.
Neurodevelopmental disorder mutations in the purine biosynthetic enzyme IMPDH2 disrupt its allosteric regulation
Published: August 2023
Summary (AI Generated):
This study helped scientists understand why IMPDH2 mutations cause disease. Earlier research had already shown that changes in the IMPDH2 gene were linked to neurodevelopmental disorders, dystonia, and other movement problems. In this study, the researchers wanted to learn exactly how these mutations affect the IMPDH2 protein.
The scientists studied seven different disease-causing IMPDH2 mutations, including two newly identified children with new (de novo) mutations. They tested how each mutated protein behaved in the laboratory. They found that all seven mutations made the IMPDH2 enzyme too active because it no longer responded properly to the body's natural "stop" signal.
Normally, when the body has enough GTP (an important building block that cells need), GTP tells IMPDH2 to slow down and stop making more. The mutated proteins ignored this signal, so they kept working even when they should have slowed down. This means these are gain-of-function mutations—the enzyme is too active, not too weak.
The researchers also used a powerful imaging method called cryo-electron microscopy (cryo-EM) to see what the IMPDH2 protein looked like. They discovered that one mutation, called L245P, made the protein spend more time in an active shape instead of fully changing into its inactive shape. Even though GTP was attached to the protein, it could not completely switch "off." This helps explain why the enzyme keeps working when it should stop.
The study found that not every mutation works in exactly the same way. One mutation (S160del) stopped the protein from forming its normal filaments, while two others (G113E and G113R) behaved differently from the rest by staying in a compressed shape while still remaining active. Even though the details were different, all seven mutations disrupted the normal control of IMPDH2.
Finally, the researchers suggested possible ideas for future treatments. Since these mutations make IMPDH2 too active, medicines that reduce IMPDH2 activity might help. They also suggested that medicines that change how IMPDH2 forms filaments could be useful for some mutations. However, these treatments have not yet been tested in patients and will require much more research.
Main takeaway: This study provided the strongest evidence so far that IMPDH2-related disorders happen because the mutated protein cannot properly turn itself off. Although different mutations affect the protein in different ways, they all leave the enzyme more active than it should be. This discovery gives scientists a much better understanding of the disease and provides a starting point for developing future treatments.
Point mutations in IMPDH2 which cause early-onset neurodevelopmental disorders disrupt enzyme regulation and filament structure
Published: March 15, 2023
Summary (AI Generated):
This study helped scientists understand how changes (mutations) in the IMPDH2 gene cause disease. Earlier studies had shown that mutations in IMPDH2 were linked to neurodevelopmental disorders, but no one knew exactly what the mutations were doing. This research looked at the protein itself to find the answer.
The researchers studied seven different IMPDH2 mutations, including two newly discovered children with changes in the gene. They found that all seven mutations had the same major problem: they stopped the IMPDH2 protein from responding to the body's normal "slow down" signal.
Normally, when the body has enough GTP (an important building block that cells need), GTP tells the IMPDH2 protein to slow down and make less. The researchers found that the mutated proteins mostly ignored this signal. Even when GTP levels were very high, the proteins kept working. This means the enzyme stays too active, which is called a gain-of-function mutation.
The scientists also used powerful microscopes to look at the shape of the IMPDH2 protein. They discovered that the mutations make it harder for the protein to fully switch into its normal "off" shape. Instead, it tends to stay in a more active shape, even when it should be slowing down. This helps explain why the enzyme keeps working when it should stop.
The study also found that not all mutations work exactly the same way. Some changed how the protein formed long chains (called filaments), while others affected how easily it changed shape. Even though the details were different, they all caused the same overall problem: poor control of IMPDH2 activity.
Finally, the researchers suggested a possible treatment idea. Since these mutations make the enzyme too active, medicines that reduce IMPDH2 activity might help restore balance. They also suggested that medicines that prevent the protein from forming filaments could be another option. However, these ideas have not yet been tested in people and will require much more research.
Main takeaway: This study showed that IMPDH2-related disorders are likely caused because the mutated IMPDH2 protein cannot properly turn itself off. Instead of slowing down when enough GTP is present, it continues making more. This is the strongest evidence so far explaining how IMPDH2 mutations cause disease, and it gives researchers a starting point for developing future treatments.
Additional Information about the 7 Mutations Discussed in this Paper (AI Generated):
G113E
This mutation was found in a child with a severe neurodevelopmental disorder. Laboratory testing showed that the IMPDH2 protein remained active even when GTP should have turned it off. Unlike normal IMPDH2, this mutation caused the protein to stay in a "compressed" shape even without GTP, which surprised the researchers because compressed proteins were previously thought to be inactive. This finding showed that the protein's shape alone does not determine whether it is active. Scientists believe this mutation disrupts the normal control of GTP production, but more research is needed to understand exactly how it causes disease.
G113R
This mutation affects the same amino acid as G113E but changes it in a different way. Like G113E, the protein ignored GTP's normal "stop" signal and stayed active when it should have slowed down. It also remained in the compressed shape without GTP, suggesting that this location is especially important for regulating IMPDH2. Although the exact disease features vary from patient to patient, the laboratory results suggest this mutation causes disease by allowing the enzyme to make too much GTP. Researchers believe it represents another example of a gain-of-function mutation.
S160del
Unlike the other mutations, S160del prevents IMPDH2 from forming its normal long filaments. Even without these filaments, the enzyme still ignored GTP and continued working when it should have stopped. This showed that loss of normal regulation does not depend only on filament formation. Scientists think this mutation causes disease through a different mechanism than many of the other variants, although the end result is similar: the enzyme stays too active. This finding suggests that different IMPDH2 mutations may require different treatment approaches in the future.
G207R
G207R behaves much more like normal IMPDH2 in its overall shape but still fails to respond correctly to GTP. The protein can change between active and inactive shapes, yet it continues working even after GTP binds. This showed researchers that simply changing shape is not enough to shut the enzyme off. Instead, additional steps in the regulatory process must also be disrupted. G207R helped demonstrate that several different molecular problems can all lead to the same disease by preventing proper regulation of IMPDH2 activity.
Q243H
The Q243H mutation also causes the enzyme to resist GTP inhibition. In laboratory studies, the protein looked very similar to the normal version, but it stayed active when GTP levels were high. This suggests the mutation changes how the protein responds to GTP rather than dramatically changing its structure. Researchers grouped Q243H with several other mutations that likely share a common disease mechanism: they shift the protein toward remaining active instead of allowing it to fully shut down. This supports the idea that IMPDH2-related disorders are caused by poor regulation rather than loss of enzyme activity.
K238R
K238R was one of the two new patients described in this paper. The child had low muscle tone (hypotonia) and global developmental delays beginning during infancy. Genetic testing found a new (de novo) IMPDH2 mutation after other testing was normal. Laboratory experiments showed that the mutation greatly reduced the protein's ability to respond to GTP, allowing it to remain active when it should have slowed down. Structurally, it behaved similarly to several nearby mutations, supporting the idea that this region of IMPDH2 is critical for regulating enzyme activity during brain development.
L245P
L245P was the other newly reported mutation. The affected child had global developmental delay, low muscle tone, congenital heart disease, hip dysplasia, unusual facial features, and abnormal posturing that may represent dystonia. This mutation became the main focus of the structural experiments. Scientists discovered that the protein strongly preferred to stay in its active form instead of fully switching into its inactive form when GTP was present. This provided the clearest explanation yet for how IMPDH2 mutations cause disease. Because L245P was studied in the greatest detail, it has become the best-understood IMPDH2 disease mutation so far.
IMPDH dysregulation in disease: a mini review
Published: February 28, 2022
Summary (AI Generated):
This article explains what scientists know about two genes called IMPDH1 and IMPDH2. These genes help the body make GTP, an important building block that cells need for energy, growth, and sending signals.
Most of the research has been done on IMPDH1, which is linked to some kinds of inherited blindness. Scientists know much less about IMPDH2, but they have recently found that changes (mutations) in this gene can cause serious brain and movement disorders.
The researchers think that IMPDH2 mutations may stop the protein from knowing when to slow down. Normally, the body has a "brake" that tells the protein to make less GTP when there is already enough. If that brake does not work, cells may make the wrong amount of GTP. This idea has not yet been proven, and the scientists say more research is needed.
The study also explains why nerve cells may be affected the most. Brain cells and the light-sensing cells in the eye need a very careful balance of these building blocks. Even small changes may make it harder for these cells to work or survive.
This paper is a review article, which means it does not report a new experiment. Instead, it summarizes what other studies have already found and points out what scientists still need to learn.
For IMPDH2, the biggest unanswered questions are:
How do the mutations change the protein?
Do they really cause the protein to ignore the body's normal "slow down" signal?
Could medicines that help control IMPDH2 activity become a treatment in the future?
The authors believe these are promising ideas, but they stress that more laboratory studies and animal studies are needed before anyone knows for sure.
Main takeaway: Scientists now know that IMPDH2 mutations can cause neurodevelopmental disorders, but they still do not fully understand how. The leading idea is that these mutations may upset the normal balance of GTP in nerve cells, but this is still being tested. Learning more about how IMPDH2 works could help researchers develop future treatments.
MPDH2: a new gene associated with dominant juvenile-onset dystonia-tremor disorder
Published: July 26, 2021
Summary (AI Generated):
This study was the first to show that changes (mutations) in the IMPDH2 gene can cause an inherited movement disorder. The researchers studied a large family in Finland where several people developed dystonia (muscle twisting), tremor (shaking), and muscle cramps during childhood or the teenage years.
The scientists found that everyone with the disorder had the same rare change in the IMPDH2 gene. Family members without the disorder did not have this change. This gave strong evidence that the mutation was causing the disease.
The mutation caused the body to destroy most of the faulty genetic instructions before they could be used. As a result, patients made much less IMPDH2 protein than normal. The researchers also found that levels of the related IMPDH1 protein were lower than expected, even though its gene was normal.
IMPDH2 helps the body make GTP, an important building block that is needed to make dopamine, a brain chemical that helps control movement. The researchers believe that having too little IMPDH2 may lower the amount of GTP available in brain cells. This could reduce dopamine production and lead to dystonia and tremor. This is their best explanation, but it has not yet been directly proven.
Interestingly, blood tests showed that most of the patients' body chemistry looked normal. This suggests that the problem may happen mainly inside certain brain cells rather than throughout the whole body.
The researchers also noted that this disorder looks similar to other genetic forms of dystonia that can improve with L-DOPA, a medicine that increases dopamine. They suggested that people with IMPDH2-related dystonia might respond to this treatment, but this was not tested in the study.
Main takeaway: This study identified IMPDH2 as a new disease-causing gene for inherited juvenile-onset dystonia and tremor. It showed that the mutation greatly reduces the amount of IMPDH2 protein, and the researchers believe this disrupts dopamine production in the brain. While the exact disease process still needs more study, this discovery was an important first step toward better diagnosis and, possibly, future treatments.
Monogenic variants in dystonia: an exome-wide sequencing study
Published: November 2020
Summary (AI Generated):
This study looked at the genes of more than 700 people with dystonia, a movement disorder that causes muscles to tighten or twist. The goal was to find genetic causes of the condition and learn which people are most likely to benefit from genetic testing.
The researchers found a genetic answer for about 1 out of every 5 people they studied. The chance of finding a genetic cause was much higher in children and in people who had dystonia along with other neurological problems, such as developmental delays, intellectual disability, or epilepsy.
One of the biggest discoveries was that IMPDH2 is very likely a disease-causing gene. The researchers found six unrelated children with new (de novo) changes in the IMPDH2 gene. These children all had neurodevelopmental disorders, and some also had dystonia. The gene changes were all located in the same important part of the protein, suggesting they disrupted how the protein normally works. Laboratory testing also showed that these gene changes affected the protein's stability and function.
The study also found that many children diagnosed with dystonic cerebral palsy actually had an underlying genetic condition instead. Among children with dystonic cerebral palsy who did not have evidence of a birth injury, about two-thirds had a disease-causing genetic change. This suggests that some children diagnosed with cerebral palsy may actually have a genetic disorder that looks very similar.
Based on their results, the researchers created a simple scoring system to help doctors decide who should receive whole exome sequencing, a type of genetic test. They recommend testing especially for people who:
Developed dystonia as children.
Have dystonia along with developmental delays, epilepsy, or other neurological problems.
Have combined movement disorders.
Have dystonic cerebral palsy without a clear birth injury.
Main takeaway: This study showed that genetic testing is especially helpful for children with dystonia and other neurological conditions. It also provided strong evidence that IMPDH2 is a disease-causing gene, helping explain why some children develop neurodevelopmental disorders, dystonia, and cerebral palsy-like symptoms. These findings can help families receive a more accurate diagnosis and may guide future research into treatments.